Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186671 | 0.83 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL3919536 | 0.83 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL7977689 | 0.83 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL8175607 | 0.83 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL13900792 | 0.81 | OPRM1 (0.63) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL7317034 | 0.79 | OPRM1 (0.67) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL4669298 | 0.77 | OPRM1 (0.58) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL8176312 | 0.75 | OPRM1 (0.67) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL2054235 | 0.74 | CYP2D6 (0.67) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL1502253 | 0.74 | CYP2D6 (0.65) | OPRM1CHRM2ADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012077133-A1 | PROCESSES FOR PREPARATION OF MONTELUKAST SODIUM AND PURIFICATION OF DIOL INTERMEDIATE | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| EP-2231613-B1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LTD (IN) | 2011-10-12 | — | — | EP | disclosed |
| US-20100292251-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| EP-2231613-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | Torrent Pharmaceuticals Ltd. (IN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009113087-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292251-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | CMA1, CYSLTR2, CYSLTR1 | OPRM1 656/4885CHRM2 762/4885ADRA2A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.